Recent Company News

• 08:08 AM ET Jul 08, 2025
  

  StreetAccount Themes Headlines (8-Jul)

• 04:30 PM ET Jun 26, 2025
  

  Teva Releases Q2 2025 Aide Memoire

• 11:44 AM ET Jun 26, 2025
  

  The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

• 04:30 PM ET Jun 25, 2025
  

  Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

• 08:26 AM ET Jun 23, 2025
  

  StreetAccount Summary - US Pre-market trading

• 03:12 AM ET Jun 23, 2025
  

  Teva Pharmaceutical's final data from PEARL real-world migraine prevention study reinforces long-term effectiveness of AJOVY ($16.95, 0.00)

• 03:00 AM ET Jun 23, 2025
  

  Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY(R) (fremanezumab) for the Prevention of Chronic and Episodic Migraine

• 07:42 AM ET Jun 21, 2025
  

  RESOLUTION trial of H. Lundbeck's Vyepti meets all primary, secondary endpoints (DKK 37.00, 0.00)